Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. More Details
High growth potential and slightly overvalued.
Share Price & News
How has Basilea Pharmaceutica's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BSLN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BSLN's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: BSLN underperformed the Swiss Biotechs industry which returned 1.3% over the past year.
Return vs Market: BSLN underperformed the Swiss Market which returned -0.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Basilea Pharmaceutica's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StHow Does Basilea Pharmaceutica's (VTX:BSLN) CEO Pay Compare With Company Performance?
3 months ago | Simply Wall StA Look At Basilea Pharmaceutica's (VTX:BSLN) Share Price Returns
5 months ago | Simply Wall StBasilea Pharmaceutica AG's (VTX:BSLN) Path To Profitability
Is Basilea Pharmaceutica undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BSLN (CHF54.35) is trading below our estimate of fair value (CHF237.46)
Significantly Below Fair Value: BSLN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BSLN is poor value based on its PE Ratio (198.3x) compared to the XE Biotechs industry average (43.3x).
PE vs Market: BSLN is poor value based on its PE Ratio (198.3x) compared to the Swiss market (24.5x).
Price to Earnings Growth Ratio
PEG Ratio: BSLN is poor value based on its PEG Ratio (3.3x)
Price to Book Ratio
PB vs Industry: BSLN has negative assets, so we can't compare its PB Ratio to the CH Biotechs industry average.
How is Basilea Pharmaceutica forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BSLN's forecast earnings growth (60.9% per year) is above the savings rate (-0.3%).
Earnings vs Market: BSLN's earnings (60.9% per year) are forecast to grow faster than the Swiss market (13% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BSLN's revenue (20.5% per year) is forecast to grow faster than the Swiss market (4.6% per year).
High Growth Revenue: BSLN's revenue (20.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BSLN's Return on Equity is forecast to be high in 3 years time
How has Basilea Pharmaceutica performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BSLN has a large one-off gain of CHF15.0M impacting its June 30 2020 financial results.
Growing Profit Margin: BSLN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BSLN has become profitable over the past 5 years, growing earnings by 30.5% per year.
Accelerating Growth: BSLN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BSLN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).
Return on Equity
High ROE: BSLN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Basilea Pharmaceutica's financial position?
Financial Position Analysis
Short Term Liabilities: BSLN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BSLN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BSLN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BSLN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: BSLN's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if BSLN's interest payments on its debt are well covered by EBIT.
What is Basilea Pharmaceutica current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BSLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BSLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BSLN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BSLN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: BSLN is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BSLN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Veitch (55 yo)
Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch served as the Pres...
CEO Compensation Analysis
Compensation vs Market: David 's total compensation ($USD1.61M) is above average for companies of similar size in the Swiss market ($USD1.17M).
Compensation vs Earnings: David 's compensation has been consistent with company performance over the past year.
|Chief Executive Officer||2.75yrs||CHF1.43m||0.012% |
|Chief Financial Officer||1.75yrs||no data||0.0046% |
|Chief Technology Officer||2.67yrs||no data||no data|
|Chief Scientific Officer||12yrs||no data||0.0046% |
|Chief Medical Officer||3yrs||no data||no data|
|Head of Corporate Communications & Investor Relations||no data||no data||no data|
|General Counsel & Corporate Secretary||3.42yrs||no data||no data|
|Head of Global Human Resources||4yrs||no data||no data|
|Head of Regulatory Affairs||15yrs||no data||no data|
|Head of Internal Services||no data||no data||no data|
|Head of Business Development & Licensing||15yrs||no data||no data|
|Head of Biology||no data||no data||no data|
Experienced Management: BSLN's management team is considered experienced (3.4 years average tenure).
|Independent Non-Executive Director||3.75yrs||CHF186.88k||no data|
|Independent Chairman of the Board||4.75yrs||CHF329.94k||0.0036% |
|Independent Non-Executive Director||7.75yrs||CHF230.17k||no data|
|Independent Non-Executive Director||12.83yrs||CHF192.13k||no data|
|Independent Vice-Chairman||3yrs||CHF216.92k||no data|
Experienced Board: BSLN's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Basilea Pharmaceutica AG's company bio, employee growth, exchange listings and data sources
- Name: Basilea Pharmaceutica AG
- Ticker: BSLN
- Exchange: SWX
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF587.155m
- Shares outstanding: 10.80m
- Website: https://www.basilea.com
Number of Employees
- Basilea Pharmaceutica AG
- Grenzacherstrasse 487
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BPMU.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Mar 2004|
|BSLN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Mar 2004|
|PK5||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Mar 2004|
|0QNA||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Mar 2004|
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It of...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 18:12|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.